Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101864 | 0.84 | IRAK4 (0.38) | IDO1TDO2IRAK4ALDH1A1TSHR | |
| SCHEMBL661287 | 0.84 | HMGCR (0.54) | HMGCRALDH1A1TSHRHTTCYP3A4 | |
| SCHEMBL10101902 | 0.74 | HSP90AB1 (0.46) | HMGCRALDH1A1TSHRHTTHSP90AB1 | |
| SCHEMBL2589156 | 0.73 | LMNA (0.34) | — | |
| SCHEMBL10101867 | 0.72 | LMNA (0.30) | — | |
| SCHEMBL10101878 | 0.72 | PDE4B (0.47) | ALDH1A1TSHRPPARACYP3A4PDE4B | |
| SCHEMBL28162947 | 0.72 | PDE4B (0.47) | ALDH1A1TSHRPPARACYP3A4PDE4B | |
| SCHEMBL10101869 | 0.71 | — | — | |
| SCHEMBL27947803 | 0.70 | ALDH1A1 (0.53) | HMGCRIDO1TDO2IRAK4ALDH1A1 | |
| SCHEMBL13019682 | 0.69 | IRAK4 (0.64) | IDO1TDO2IRAK4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | HMGCR 74/4885IDO1 2049/4885TDO2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.